These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 16675042

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
    Irwin N, Clarke GC, Green BD, Greer B, Harriott P, Gault VA, O'Harte FP, Flatt PR.
    Biochem Pharmacol; 2006 Sep 14; 72(6):719-28. PubMed ID: 16859646
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD, Gault VA, O'Harte FP, Flatt PR.
    Diabetes Obes Metab; 2005 Sep 14; 7(5):595-604. PubMed ID: 16050953
    [Abstract] [Full Text] [Related]

  • 5. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
    Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR, Gault VA.
    Biochem Pharmacol; 2009 Oct 15; 78(8):1008-16. PubMed ID: 19523458
    [Abstract] [Full Text] [Related]

  • 6. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
    Irwin N, Gault VA, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR, O'Harte FP.
    Biol Chem; 2005 Jul 15; 386(7):679-87. PubMed ID: 16207089
    [Abstract] [Full Text] [Related]

  • 7. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb 15; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 8. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA, Kerr BD, Harriott P, Flatt PR.
    Clin Sci (Lond); 2011 Aug 15; 121(3):107-17. PubMed ID: 21332446
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.
    Gault VA, Hunter K, Irwin N, Greer B, Green BD, Harriott P, O'Harte FP, Flatt PR.
    Biol Chem; 2007 Feb 15; 388(2):173-9. PubMed ID: 17261080
    [Abstract] [Full Text] [Related]

  • 12. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 15; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 13. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
    Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR.
    Diabetes; 2005 Aug 15; 54(8):2436-46. PubMed ID: 16046312
    [Abstract] [Full Text] [Related]

  • 14. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
    Parker JC, Irwin N, Lavery KS, Green BD, O'Harte FP, Gault VA, Flatt PR.
    Biol Chem; 2007 Feb 15; 388(2):221-6. PubMed ID: 17261085
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in rats.
    Irwin N, Francis JM, Flatt PR.
    Biol Chem; 2011 Oct 15; 392(10):909-18. PubMed ID: 21851286
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide.
    Alaña I, Hewage CM, Malthouse JP, Parker JC, Gault VA, O'Harte FP.
    Biochem Biophys Res Commun; 2004 Dec 03; 325(1):281-6. PubMed ID: 15522230
    [Abstract] [Full Text] [Related]

  • 19. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
    Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P, O'Harte FP, Flatt PR.
    Biol Chem; 2004 Sep 03; 385(9):845-52. PubMed ID: 15493880
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice.
    Irwin N, Montgomery IA, Flatt PR.
    Br J Nutr; 2012 Jul 14; 108(1):46-56. PubMed ID: 22260799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.